DYN•benzinga•
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path
Summary
JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor concerns over data updates.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 21, 2025 by benzinga